Non-pharmaceutical interventions and the emergence of pathogen variants

Ben Ashby[1,2,*], Cameron A. Smith[2] and Robin N. Thompson[3,4]

1. Department of Mathematics, Simon Fraser University, Burnaby, BC, Canada

2. Department of Mathematical Sciences, University of Bath, Bath, UK

3. Mathematics Institute, University of Warwick, Coventry, UK

4. Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research,

9   University of Warwick, Coventry, UK

*Corresponding author: benashbyevo@gmail.com

Keywords: pathogen evolution, transmissibility, immune escape, cross-immunity, social

distancing, lockdowns

ABSTRACT

Non-pharmaceutical interventions (NPIs), such as social distancing and contact tracing, are

important public health measures that can reduce pathogen transmission. In addition to

playing a crucial role in suppressing transmission, NPIs influence pathogen evolution by

mediating mutation supply, restricting the availability of susceptible hosts, and altering the

strength of selection for novel variants. Yet it is unclear how NPIs might affect the

emergence of novel variants that are able to escape pre-existing immunity (partially or

fully), are more transmissible, or cause greater mortality. We analyse a stochastic two-strain

epidemiological model to determine how the strength and timing of NPIs affects the

emergence of variants with similar or contrasting life-history characteristics to the wildtype.

We show that, while stronger and timelier NPIs generally reduce the likelihood of variant

emergence, it is possible for more transmissible variants with high cross immunity to have a

greater probability of emerging at intermediate levels of NPIs. This is because intermediate

levels of NPIs allow an epidemic of the wildtype that is neither too small (facilitating high

mutation supply), nor too large (leaving a large pool of susceptible hosts), to prevent a novel

variant becoming established in the host population. However, since one cannot predict the

characteristics of a variant, the best strategy to prevent emergence is likely to be

implementation of strong, timely NPIs.

INTRODUCTION

Understanding the impact of interventions for infectious disease control on pathogen

evolution is a major challenge at the interface of public health and evolutionary biology

(Porco *et al.*, 2005; Read *et al.*, 2015; Day *et al.*, 2020). To date, most theoretical

explorations of how interventions mediate pathogen evolution have focused on the impact

of vaccinations on antigenic evolution (McClean, 1995; Wilson *et al.*, 1998; van Boven *et al.*,

2005), changes in pathogen population structure (Lipsitch, 1997; Watkins *et al.*, 2015), and

virulence evolution (Gandon *et al.*, 2001, 2003; André & Gandon, 2006; Ganusov & Antia,

2006; Gandon & Day, 2007; Williams & Day, 2008; Miller & Metcalf, 2019). For example,

imperfect vaccines have been shown both theoretically (Gandon *et al.*, 2001, 2003) and

empirically (Read *et al.*, 2015) to select for higher virulence by allowing vaccinated hosts to

continue transmitting while infected (for a discussion of when this might occur see Bull &

Antia, 2022). Certain interventions may therefore have unintended consequences for

pathogen evolution and long-term negative impacts on the host population. Recently, there

has been renewed interest in the effects of vaccination programmes on pathogen evolution

and subsequent transmission during the COVID-19 pandemic (Bieniasz, 2021; Cobey *et al.*,

2021; Gog *et al.*, 2021; Saad-Roy *et al.*, 2021; Sah *et al.*, 2021; Thompson *et al.*, 2021). This

includes the potential for new pathogen variants (otherwise referred to as "mutants" or

"strains" in the literature), which may be more transmissible, more virulent, or able to

escape naturally- or vaccine-induced immunity. However, while the impact of vaccination

on pathogen evolution has been the subject of sustained theoretical interest, there has

been relatively little attention directed at the effects of non-pharmaceutical interventions

on pathogen evolution (Hartfield & Alizon, 2014; Day *et al.*, 2020; Gurevich *et al.*, 2021).

NPIs, including social distancing, improved hygiene practices, school closures, lockdowns,

quarantining exposed or isolating infected individuals, contact tracing, and various other

measures, are important tools for managing outbreaks of infectious diseases. NPIs are

particularly crucial during the early stages of an epidemic when pharmaceutical

interventions (including vaccines) may not be available (e.g. for a novel pathogen). Although

various NPIs have been used during previous epidemics of seasonal and pandemic influenza,

Ebola, and Zika, among others, NPIs were almost universally adopted (to an extent not seen

before) across the globe during the COVID-19 pandemic. Some NPIs, such as mask-wearing

and national lockdowns, have been credited with drastically reducing cases and bringing

epidemics under control, both prior to and in conjunction with vaccination programmes

(Thompson *et al.*, 2020; Li *et al.*, 2021; Liu *et al.*, 2021; Moore *et al.*, 2021). Given their

widespread adoption during the COVID-19 pandemic, it is likely that NPIs will feature heavily

in public health responses to future epidemics or pandemics, and therefore we must

improve our understanding of how NPIs affect both pathogen transmission and evolution.

The emergence of a novel pathogen variant occurs in two stages. First, the variant must be

generated through mutation or recombination ("appearance"). Mutation supply governs the

appearance of a new variant and depends on the rate at which the pathogen replicates in

the host population (determined by the number of infected hosts), the mutation rate, and

the number of mutations required to generate the variant. By reducing opportunities for

transmission, NPIs effectively lower the rate at which the pathogen replicates, and hence

lower the mutation supply. NPIs should therefore always make the appearance of novel

variants less likely by restricting mutation supply.

If a variant does appear, then the second stage for emergence requires sustained

transmission between hosts ("establishment"). It should be noted that many variants are

likely to appear that have little or no impact on pathogen transmission or virulence. Variants

may appear but remain undetected as they are unable to become established due to

selection (if the variant is less fit than the wildtype) (Kucharski & Gog, 2012) or stochastic

extinction (if by chance the variant dies out before it can infect many hosts) (Ferguson &

Galvani, 2003; Abu-Raddad & Ferguson, 2004; Gog, 2008). NPIs are likely to have more

complex effects on the establishment phase as they influence the strength of selection, the

likelihood of stochastic extinction, and the availability of susceptible hosts. For example,

stronger NPIs will slow the rate at which a variant can spread and will increase the likelihood

of stochastic extinction, but will also change how immunity accumulates in the host

population.

Previous theory has demonstrated the importance of the relationship between the

appearance and establishment phases of variant emergence in the absence of NPIs

(Lourenço & Recker, 2010; Hartfield & Alizon, 2014). In particular, Hartfield and Alizon

(2014) analytically derived the probability of a strongly adapted variant with full cross-

immunity ($R_0 \gg 1$) emerging from a weakly adapted strain ($R_0 \approx 1$), accounting for

depletion of susceptible hosts, mutation supply, and stochastic extinction (R_0 is the basic

reproduction number, which represents the expected number of secondary infections

caused by a pathogen in an otherwise susceptible population). The ongoing depletion of

susceptible hosts was shown to be especially important for suppressing the emergence of a

novel variant. Arinaminpathy & McLean (2009) modified a modelling approach by Antia *et*

al. (2003) to investigate the emergence and establishment of a pathogen that is adapting to

transmit more effectively in humans, providing a mathematical approach for monitoring

outbreaks for signs of pathogen emergence, again in the absence of NPIs.

Here, we analyse a stochastic model of pathogen evolution to explore the effects of NPIs on

the emergence of novel variants which may have no, partial, or full cross-immunity. We

show how the strength and timing of NPIs, along with the life-history characteristics of the

variant, affect its emergence and impact on the host population.

METHODS

To explore the key factors underlying the emergence of novel variants in a simple setting,

we model infectious disease dynamics in a well-mixed, homogeneous host population over

a relatively short period, ignoring host births and natural mortality for simplicity (see Fig. 1

for a model schematic). We restrict our model to two strains, a wildtype (w) and a variant

(v). The transmission rates of both strains are equally affected by NPIs, as determined by

the parameter r ($0 \leq r \leq 1$). We assume that, for each strain, the baseline transmission

rate is β_i ($i \in \{w, v\}$), the disease-associated mortality rate (virulence) for single infections

is α_i, and the average infectious period is $1/\gamma$.

Following a primary infection, an individual is assumed to be fully immune to the strain by

which they were infected, and to have acquired partial cross-immunity, c, to the other

strain ($0 \leq c \leq 1$). Thus, when $c = 0$ there is no cross-immunity between strains and when

$c = 1$ there is full cross-immunity. Cross-immunity is assumed to only reduce a host's

susceptibility to infection by the other strain, such that the probability of successful

infection at each potential infectious contact is reduced by a factor of $(1 - c)$ (Thompson *et*

al., 2019b). The order in which a host is infected does not affect the outcome of infection by

the first or second strain (i.e. the virulence of a strain is the same regardless of whether the

host experiences a primary or secondary infection). We assume that the variant differs from

the wildtype at a single genetic locus, and that mutations occur between strains at overall

rate ξ in each infected host, leading to coinfections by both strains. The virulence for

coinfections is assumed to be the average of the wildtype and variant, $\alpha_C = \frac{1}{2}(\alpha_w + \alpha_v)$.

At time, t, we use the following notation: S_t is the number of hosts that are fully susceptible

to both the wildtype and the variant (initially all individuals are susceptible to both strains),

I_t^i is the number of primary infections by strain i (i.e. individuals who are currently infected

by strain i and have never previously been infected by either strain), I_t^{ij} is the number of

secondary infections by strain j following recovery from primary infection by strain i, C_t is

the number of coinfections, R_t^i is the number of individuals who have recovered from a

primary infection by strain i (and are immune to strain i, and not yet infected by the other

strain), and R_t the number of individuals who have recovered from both strains (and are

therefore immune to both strains). In the absence of NPIs, the per-capita force of infection

on fully susceptible hosts for strain i is denoted $\lambda_t^i = \beta_i(I_t^i + I_t^{ji} + C_t)$ ($i \neq j$ throughout).

We assume that NPIs are either triggered (i) at the start of the epidemic and remain in place

for the rest of a simulation, or (ii) when the total disease prevalence, $\widetilde{I}_t = (I_t^w + I_t^v + I_t^{wv} +$

$I_t^{vw} + C_t)/N$, exceeds a threshold of $\epsilon_{on} > 0$ and remain in place until $\widetilde{I}_t$ falls below a

second threshold, $\epsilon_{off} > 0$, where $\epsilon_{on} > \epsilon_{off}$. Primary infections by strain i occur at per-

capita rate λ_t^i before NPIs are triggered and $\lambda_t^i(1 - r)$ after NPIs are triggered. Similarly,

secondary infections and coinfections (not arising from mutation) occur at per-capita rates

$\lambda_t^i(1-c)$ and $\lambda_t^i(1-r)(1-c)$ before and after NPIs are triggered, respectively. Assuming

mutations are relatively rare ($\xi \ll \gamma$), the effective (or time-varying) reproduction number

(Cori *et al.*, 2013; Thompson *et al.*, 2019a) of strain i at time t in the absence of restrictions

is given by:

$$\mathcal{R}_t^i \approx \frac{\beta_i}{\alpha_i + \gamma}\left(S_t + (I_t^j + R_t^j)(1-c)\right). \tag{1}$$

We run simulations of the model using the direct method version of the Gillespie stochastic

simulation algorithm (Gillespie, 1977) using a population size of $N = 100{,}000$ and initial

condition $\{S_0, I_0^w, I_0^v\} = \{N - 100{,}100{,}0\}$, with 1,000 simulations per parameter set unless

otherwise stated. Since here we are only interested in the emergence of a new variant, we

fix the following parameters as they do not qualitatively change our results: $\xi = 5 \times 10^{-5}$,

$\gamma = \frac{1}{5}$, $\beta_w = \frac{\mathcal{R}_0^w(\alpha_w + \gamma)}{N}$, and $\mathcal{R}_0^w = 3$. We choose β_v such that the variant is less $\left(\frac{\beta_v}{\beta_w} < 1\right)$,

equally $\left(\frac{\beta_v}{\beta_w} = 1\right)$, or more $\left(\frac{\beta_v}{\beta_w} > 1\right)$ transmissible than the wildtype. We also vary whether

NPIs are on for the duration of an epidemic or have trigger thresholds $\left(\epsilon_{on} = 0.01, \epsilon_{off} = \right.$

$\left. 0.002\right)$, the level of cross-immunity between the wildtype and variant ($0 \leq c \leq 1$), the

strength of NPIs ($0 \leq r \leq 1$), the virulence of the wildtype $\left(\alpha_w \in \left\{\frac{\gamma}{499}, \frac{\gamma}{49}, \frac{\gamma}{4}\right\}\right.$; giving an

infection fatality rate for the wildtype of $\frac{\alpha_w}{\alpha_w + \gamma} \in \left\{\frac{1}{500}, \frac{1}{50}, \frac{1}{5}\right\}\right)$, and the relative virulence of

the variant $\left(\frac{\alpha_v}{\alpha_w} \in \{1,2,3\}\right)$. We define emergence by concluding that the variant has

emerged if the frequency of infections caused by the variant exceeds 10% at any time

during a simulation. Simulations are terminated when the number of hosts infected reaches

0.

Figure 1 – Model schematic. Arrows show transitions between classes at the given rates,

with parameters as described in the main text.

RESULTS

WHEN IS THE VARIANT FITTER THAN THE WILDTYPE?

We consider a scenario in which the variant is initially rare relative to the wildtype. The variant is fitter than the wildtype when $\mathcal{R}_t^v > \mathcal{R}_t^w$, which requires:

$$\frac{\mathcal{R}_t^v}{\mathcal{R}_t^w} = \frac{\beta_v(\gamma + \alpha_w)\big(S_t + (I_t^w + R_t^w)(1 - c)\big)}{\beta_w(\gamma + \alpha_v)\big(S_t + (I_t^v + R_t^v)(1 - c)\big)}$$

$$\approx \frac{\beta_v(\gamma + \alpha_w)}{\beta_w(\gamma + \alpha_v)}\left(1 + \frac{(I_t^w + R_t^w)(1 - c)}{S_t}\right) > 1 \qquad (2)$$

Hence, a variant is always fitter when it is at least as transmissible as the wildtype, has virulence than or equal to the wildtype, and cross immunity is less than complete ($c < 1$). However, a less transmissible variant may also be fitter provided the wildtype has already infected a sufficient proportion of the population and there is not full cross immunity. Clearly, when $c < 1$ the fitness of the variant will increase relative to the wildtype as the pool of susceptible hosts for the latter is depleted. Note that NPIs do not directly affect whether a variant is fitter than the wildtype since there is no differential effect on transmission. NPIs will, however, affect mutation supply (and hence the appearance of the variant) and the rate at which the variant can spread (establishment) by modifying the transmission rate and the availability of susceptible hosts.

TIMELY AND PERSISTENT NPIS

We initially consider the case when NPIs are triggered immediately and remain in place throughout the epidemic (Fig. 2). When NPIs are sufficiently strong to prevent the wildtype

from initially spreading $\left(r > 1 - \frac{1}{\mathcal{R}_0^w}\right)$, then unless the mutation rate is very high, it is

unlikely that the variant will appear before the wildtype is driven extinct. Thus, the

probability of a variant emerging is close to 0 whenever $r > 1 - \frac{1}{\mathcal{R}_0^w}$ regardless of

transmissibility or cross immunity (Fig. 2i-l). When $r < \min\left\{1 - \frac{1}{\mathcal{R}_0^w}, 1 - \frac{1}{R_t^v}\right\}$, the

probability of a variant emerging depends on the relative transmissibility of the variant, the

strength of cross immunity, and the strength of NPIs. When cross immunity and NPIs are

both relatively weak, there is a high probability of variants emerging (Fig. 2i-l). This is

because there is a high mutation supply (weak restrictions) to generate the variant and a

large pool of susceptible individuals to exploit.

When the variant is less or equally as transmissible as the wildtype, there is an inverse effect

of cross immunity and NPIs on the probability of the variant emerging: weaker NPIs require

stronger cross immunity, and vice versa, to prevent the variant emerging (Fig. 2i-j). When

the variant is sufficiently more transmissible, however, it has a high probability of emerging

even when cross immunity is strong (Fig. 2k-l). Most notably, the variant is more likely to

emerge for intermediate NPIs when cross-immunity is very high or complete ($c \approx 1$). This is

because, when NPIs are weak ($r \ll 1$), there is a large outbreak of the wildtype, which

leads to a high mutation supply but also rapidly depletes the pool of hosts for the variant

due to cross-immunity (Fig. 3a, d). Thus, while a variant is likely to appear, it is unlikely to

spread widely in the population due to herd immunity (Ashby & Best, 2021). When NPIs are

stronger (but not too strong) the wildtype causes a smaller outbreak, leading to a lower

build-up of cross immunity in the population while still maintaining a sufficient mutation

supply for the variant to appear with high probability (Fig. 3b, e). This creates just the right

conditions to allow the variant to sweep into the population. As a result of this

phenomenon, it is possible for total deaths (for both strains) to peak at intermediate NPIs

when the variant is both more transmissible and more deadly than the wildtype (Fig. 4).

These results are robust to variation in virulence (Fig. S1-S3).

Figure 2 – Effects of the strength of NPIs (r), strength of cross immunity (c), and relative

transmissibility of the variant (β_v/β_w; as indicated at the top of each column) on: (a)-(d)

median proportion of hosts infected by the variant; (e)-(h) median total deaths (per 100k)

for both strains; and (i)-(l) the probability of the variant emerging (reaching a frequency of

at least 0.1). Each measure is calculated over the full duration of each simulation. NPIs are

triggered at the start of each simulation and remain in place throughout. Other parameters

as described in the main text, with: $\frac{\alpha_w}{\alpha_w+\gamma} = \frac{1}{50}$ and $\alpha_v = \alpha_w$.

Figure 3 – Simulations with full cross immunity and a 50% more transmissible variant

$\left(\frac{\beta_v}{\beta_w} = 1.5\right)$ for different levels of NPIs (triggered at the start of the simulation and in place

throughout): (a, d) no NPIs ($r = 0$); (b, e) intermediate NPIs ($r = 0.5$); (c, f) strong NPIs

($r = 0.75$). (a-c) Proportion of the entire population currently infected by the wildtype

(blue) and by the variant (red), with coinfecteds contributing to both counts. (d-f) Frequency

of the variant. Simulations were terminated when the pathogen went extinct. Other

parameters as described in the main text, with: $\frac{\alpha_w}{\alpha_w + \gamma} = \frac{1}{50}$ and $\alpha_v = \alpha_w$.

Figure 4 – Effects of NPIs (r) and the relative virulence (α_v/α_w) of a twice as transmissible

variant ($\beta_v/\beta_w = 2$) on total deaths (per 100k) when there is full cross immunity ($c = 1$)

and NPIs are introduced at the start of the simulation and remain in place throughout. Plots

show the median number of deaths (black) along with the upper and lower quartiles (grey).

Other parameters as described in the main text with $\frac{\alpha_w}{\alpha_w+\gamma} = \frac{1}{50}$.

We now consider the case where NPIs are only triggered when disease prevalence is above

a non-zero threshold ($\epsilon_{on} = 0.01$) and are removed when disease prevalence falls below a

second threshold ($\epsilon_{off} = 0.002$) (Fig. 5). Hence, NPIs are triggered when 1% of the host

population is infected by either strain, and are removed when only 0.2% are infected. There

are three notable effects of having triggering thresholds for NPIs. First, since NPIs are not in

place from the start, a non-negligible number of deaths now occur over the full range of NPI

strengths (Fig. 5e-h). Second, as the initial mutation supply is no longer curtailed by NPIs,

variants can emerge for $r > 1 - \frac{1}{R_0^W}$ (Fig. 5j-l). Third, more transmissible variants which

experience sufficiently high cross immunity with the wildtype ($c \approx 1$) are still most likely to

emerge at intermediate NPIs, but now the variant remains highly likely to emerge when

NPIs are strong but fall below the relaxation threshold ϵ_{off} (compare Fig. 2k-l and Fig. 5k-l).

However, if the variant is also more virulent, then deaths still peak when NPI intensity is

intermediate (Fig. 6). These results are robust to variation in virulence (Fig. S4-S6).

Figure 5 – Effects of the strength of NPIs (r) when there are NPI trigger thresholds, strength

of cross immunity (c), and relative transmissibility of the variant (β_v/β_w; as indicated at the

top of each column) on: (a)-(d) median proportion of hosts infected by the variant; (e)-(h)

median total deaths (per 100k) for both strains; and (i)-(l) the probability of the variant

emerging (reaching a frequency of at least 0.1). The NPI trigger thresholds are $\epsilon_{on} = 0.01$

and $\epsilon_{off} = 0.002$ (i.e. NPIs are triggered when 1% of the host population is infected by

either strain, and are removed when only 0.2% are infected). Other parameters as described

in the main text, with: $\frac{\alpha_w}{\alpha_w + \gamma} = \frac{1}{50}$ and $\alpha_v = \alpha_w$.

Figure 6 – Effects of NPIs (r) and the relative virulence (α_v/α_w) of a variant that is twice as

transmissible ($\beta_v/\beta_w = 2$) on total deaths (per 100k) when there is full cross immunity

($c = 1$) and NPIs have trigger and relaxation thresholds ($\epsilon_{on} = 0.01$ and $\epsilon_{off} = 0.002$).

Plots show the median number of deaths (black) along with the upper and lower quartiles

(grey). Other parameters as described in the main text with $\frac{\alpha_w}{\alpha_w+\gamma} = \frac{1}{50}$.

DISCUSSION

The emergence of novel variants depends on the interaction between mutation supply and

the strength of selection, both of which are influenced by NPIs. Here, we have shown how

NPIs and the stage of an epidemic at which they are triggered affect the emergence of novel

variants with a range of life-history characteristics. Although stronger, consistent

implementation of NPIs generally reduces the likelihood that a novel variant will emerge,

more transmissible variants that exhibit a high degree of cross immunity with the wildtype

may be most likely to emerge when NPIs are enacted early but are of insufficient strength to

drive the wildtype extinct quickly (Fig. 2k, Fig. 3b). This echoes a theoretical result for

vaccination, which suggests that imperfect vaccination may provide the optimal conditions

for vaccine-escape variants to emerge (van Boven *et al.*, 2005; Saad-Roy *et al.*, 2021). This is

because imperfect vaccination can allow a significant mutation supply while also exerting

selective pressure for vaccine-escape variants.

In the results shown here, when NPIs are weak, a large outbreak of the wildtype can occur.

This allows a variant to appear (high mutation supply) but prevents it from spreading widely

due to the accumulation of cross immunity in the host population (the variant cannot

establish). When NPIs are at an intermediate level, however, there may be sufficient

mutation supply to allow the variant to appear but insufficient accumulation of cross

immunity from the wildtype. The higher transmissibility of the variant then facilitates its

establishment. If the variant is also sufficiently more virulent, then it is possible that this will

increase the overall number of deaths (Fig. 4). These patterns are broadly when NPIs have

trigger and relaxation thresholds based on disease prevalence (Fig. 5, Fig. 6), but in general

the variant is able to emerge over a wider set of conditions compared to when NPIs are

introduced at the start of the epidemic and are maintained throughout.

While it is possible that intermediate strength or timely NPIs may occasionally lead to more

negative outcomes than weaker or delayed NPIs as described above, we note that this

requires the variant to have a rather specific set of characteristics. Since it is challenging to

predict the phenotypic characteristics of novel variants, we contend that the optimal

strategy to prevent variants of concern arising is almost always to ensure that NPIs are

strong, timely and implemented consistently. If this is done, then the mutation supply is

constrained over the duration of the epidemic, preventing novel variants from appearing in

the first place.

Of course, when deciding to implement strong and timely NPIs, a range of factors must be

considered. For example, the wildtype might fade out without invading the host population

in the absence of NPIs (Gandon *et al.*, 2013; Chabas *et al.*, 2018). In that case, it may be

unnecessary to introduce costly NPIs (Thompson *et al.*, 2018). On the other hand, it may be

impossible to contain or eradicate a pathogen, even if strong NPIs are introduced

(Thompson *et al.*, 2020). In that scenario, potential negative non-disease health outcomes

of NPIs should be considered, particularly if NPIs are maintained over long periods.

Comparing the costs and benefits of a range of public health measures is an essential area

of research (Newbold *et al.*, 2020; Sandmann *et al.*, 2021; Smith *et al.*, 2022). As we have

demonstrated, potential evolutionary consequences of different NPIs could be an important

component of such analyses.

Our study is related to previous work by Hartfield and Alizon (2014), who explored the

relationship between the appearance and establishment phases of variant emergence when

the wildtype is weakly adapted to the host ($R_0 \approx 1$) and the variant is strongly adapted

($R_0 \gg 1$). Crucially, Hartfield and Alizon (2014) found that when the R_0 of the wildtype is

intermediate (but close to 1), then a variant can emerge that has a lower R_0, which is similar

to our finding that intermediate NPIs can facilitate variant emergence since reducing the

spread of the wildtype leaves a larger pool of susceptible hosts for the variant. Conversely,

the fact that greater spread of the wildtype or high levels of vaccination can reduce the

likelihood of a variant with high cross-immunity emerging is also well-established in the

literature. While Hartfield and Alizon's model can be readily adapted to account for NPIs by

multiplying the reproductive numbers by $(1 - r)$, their analytic approach considers

scenarios in which $R_0 \approx 1$ for the wildtype and there is full cross-immunity with the variant

($c = 1$). We were unable to use a similar analytic approach to Hartfield and Alizon (2014)

due to additional complexities in our model. Specifically, the assumption of less-than-full

cross-immunity is particularly challenging from an analytic perspective, as one would need

to track both the depletion of fully susceptible hosts (S_t) and hosts that have partial cross-

immunity (R_t^w).

The present study differed from this previous work in several key aspects. In particular, we

explored the probability of variant emergence and the effects of overall mortality when the

wildtype has $R_0 \gg 1$ (i.e. the wildtype is likely to cause a large-scale epidemic), when cross-

immunity may be partial or absent ($c < 1$), and when NPIs of varying strengths are

implemented consistently or with trigger and relaxation thresholds. The differences in our

modelling assumptions allowed us to show how interactions between NPIs, cross-immunity,

and virulence can mediate not only the emergence of novel variants, but also how under

certain circumstances moderate NPIs could theoretically increase overall deaths if a new

variant is more virulent than the wildtype.

To explore the potential effects of NPIs on the emergence of pathogen variants, we made

several simplifying assumptions in our modelling approach. First, we assumed that there is

no differential effect of NPIs on the wildtype and the variant transmission rates. While this is

often likely to be true, it is possible that NPIs may affect some strains more than others. For

example, if symptomatic people are more likely to be identified and isolated, then selection

may favour variants that cause more presymptomatic or asymptomatic infections or that

have a longer incubation period. Similarly, different variants may have different generation

times (Hart *et al.*, 2022), and if individuals are isolated following contact tracing, then

variants with shorter generation times may be favoured. Second, our model does not

include population heterogeneity or contact structure, both of which affect pathogen

transmission and the emergence of variants (Chabas *et al.*, 2018). If, for example, some

individuals are less likely to adhere to NPIs, then there may be an increased opportunity for

new variant appearance. This effect may be particularly pronounced if those individuals

belong to specific groups in a population within which transmission may occur. Third, for

simplicity we assumed that the wildtype and variant only differed by one mutation at a

single genetic locus with potential pleiotropic effects on antigenicity, transmissibility, and

virulence. In reality, genetic and phenotypic landscapes are complex, with multiple

mutations sometimes required to transition between variants, some of which may be

initially neutral or deleterious due to epistasis. For example, several major variants of SARS-

CoV-2 exhibit large numbers of mutations, especially in the spike protein (Tegally *et al.*,

2021; Volz *et al.*, 2021). If a large number of mutations are required to substantially escape

host immunity then epistasis may severely constrain pathogen evolution with

immunocompromised hosts potentially crucial for antigenic evolution (Smith & Ashby,

2022). Fourth, we assumed that when NPIs were active, they were fixed at a constant level,

which may be reasonable if they are in place for a relatively short period of time. However,

if one were to consider multi-wave epidemics over a longer period of time (e.g. due to the

relaxation of NPIs, seasonality, waning immunity, or pathogen evolution), then it would be

more realistic to vary the strength of NPIs as disease prevalence changes rather than just

having trigger and relaxation thresholds. It may also be difficult to accurately estimate the

current state of the epidemic, especially during the early stages when widespread testing

may be unavailable. Finally, we did not model the effects of vaccination programmes on the

potential for new variants to emerge, as these have been considered extensively elsewhere

(McClean, 1995; Wilson *et al.*, 1998; van Boven *et al.*, 2005; Day *et al.*, 2008; Cobey *et al.*,

2021; Gog *et al.*, 2021; Saad-Roy *et al.*, 2021; Thompson *et al.*, 2021).

Despite these simplifications to our model, our results allowed us to demonstrate important

principles about the effects of NPIs on the emergence on variants. Our findings are likely to

be qualitatively robust with respect to the effects of NPIs, and the framework that we have

provided can be readily extended. For instance, some differential effects of NPIs are simply

equivalent to altering the transmissibility of the different strains. Population heterogeneity

and contact structure both affect pathogen transmission, and so are also likely to affect the

initial spread of variants, potentially allowing variants to gain a foothold in a subset of the

population. Conversely, a more complex genetic and phenotypic landscape would likely

make it more difficult for variants to emerge, for example due to epistasis (Smith & Ashby,

2022). One could crudely model this by reducing the mutation supply in our model to mimic

the lower rate of accumulating multiple mutations, which would quantitatively, but not

qualitatively, change our results.

In conclusion, NPIs have significant impacts on the emergence of novel variants by

mediating both the mutation supply and the strength of selection. Although stronger NPIs

generally reduce the probability that a new variant of concern will emerge, there are certain

circumstances – namely, when cross immunity is high and the variant is more transmissible

– where NPIs of intermediate strength lead to an increased probability of variant

emergence, potentially leading to a higher level of mortality. However, this requires a very

particular set of circumstances and one cannot predict where a variant will emerge in

phenotype space (i.e. its transmissibility, virulence, and level of cross immunity). The

optimal strategy to prevent variants emerging is therefore to ensure that NPIs are

sufficiently strong to drive the wildtype extinct, thereby cutting off the mutation supply.

AUTHOR CONTRIBUTIONS

BA conceived the study and conducted the investigation. BA and RNT discussed the original

ideas and results. CAS carried out additional analyses. BA and RNT wrote the manuscript.

DATA ACCESSIBILITY

Source code for the simulations is available in the online *Supplementary Materials* and at

https://github.com/ecoevogroup/Ashby_Thompson_2021.

ACKNOWLEDGEMENTS

BA and CAS are supported by the Natural Environment Research Council (grant numbers

NE/N014979/1 (BA) and NE/V003909/1 (BA and CAS)).

REFERENCES

Abu-Raddad, L.J. & Ferguson, N.M. 2004. The impact of cross-immunity, mutation and

stochastic extinction on pathogen diversity. *Proc. R. Soc. B* **271**: 2431–8.

André, J.-B. & Gandon, S. 2006. Vaccination, Within-Host Dynamics, and Virulence Evolution.

Evolution. **60**: 13-23.

Antia, R., Regoes, R.R., Koella, J.C. & Bergstrom, C.T. 2003. The role of evolution in the

emergence of infectious diseases. *Nature* **426**: 658–661.

Arinaminpathy, N. & McLean, A.R. 2009. Evolution and emergence of novel human

infections. *Proc. R. Soc. B Biol. Sci.* **276**: 3937–3943.

Ashby, B. & Best, A. 2021. Herd immunity. *Curr. Biol.* **31**: R174–R177.

Bieniasz, P.D. 2021. The case against delaying Severe Acute Respiratory Syndrome

Coronavirus 2 (SARS-CoV-2) mRNA vaccine boosting doses. *Clin. Infect. Dis.* ciab070.

Bull, J.J. & Antia, R. 2022. Which "imperfect vaccines" encourage the evolution of higher

virulence? *Evol. Med. Public Heal.* **10**: 202–213.

Chabas, H., Lion, S., Nicot, A., Meaden, S., van Houte, S., Moineau, S., *et al.* 2018.

Evolutionary emergence of infectious diseases in heterogeneous host populations.

PLoS Biol. **16**: e2006738.

Cobey, S., Larremore, D.B., Grad, Y.H. & Lipsitch, M. 2021. Concerns about SARS-CoV-2

evolution should not hold back efforts to expand vaccination. *Nat. Rev. Immunol.* **21**:

330–335.

Cori, A., Ferguson, N.M., Fraser, C. & Cauchemez, S. 2013. A new framework and software to estimate time-varying reproduction numbers during epidemics. *Am. J. Epidemiol.* **178**: 1505–12.

Day, T., Galvani, A., Struchiner, C. & Gumel, A. 2008. The evolutionary consequences of vaccination. *Vaccine* **26**: C1-3.

Day, T., Gandon, S., Lion, S. & Otto, S.P. 2020. On the evolutionary epidemiology of SARS-CoV-2. *Curr. Biol.* **30**: R849-R857.

Ferguson, N.M. & Galvani, A.P. 2003. The impact of antigenic variation on pathogen population structure, fitness and dynamics. In: *Antigenic Variation* (A. Craig & A. Scherf, eds), pp. 403–432.

Gandon, S. & Day, T. 2007. The evolutionary epidemiology of vaccination. *J. R. Soc. Interface* **4**: 803–817.

Gandon, S., Hochberg, M.E., Holt, R.D. & Day, T. 2013. What limits the evolutionary emergence of pathogens? *Philos. Trans. R. Soc. B Biol. Sci.* **368**: 20120086.

Gandon, S., Mackinnon, M., Nee, S. & Read, A. 2003. Imperfect vaccination: Some epidemiological and evolutionary consequences. *Proc. R. Soc. B Biol. Sci.* **270**: 1129–1136.

Gandon, S., Mackinnon, M.J., Nee, S. & Read, A.F. 2001. Imperfect vaccines and the evolution of pathogen virulence. *Nature* **414**: 751–6.

Ganusov, V. V. & Antia, R. 2006. Imperfect Vaccines and the Evolution of Pathogens Causing Acute Infections in Vertebrates. *Evolution.* **60**: 957-969.

Gillespie, D.T. 1977. Exact stochastic simulation of coupled chemical reactions. *J. Phys. Chem.* **93555**: 2340–2361.

Gog, J.R. 2008. The impact of evolutionary constraints on influenza dynamics. *Vaccine* **26**:

C15–C24.

Gog, J.R., Hill, E.M., Danon, L. & Thompson, R.N. 2021. Vaccine escape in heterogeneous

populations: insights for SARS-CoV-2 from a simple model. *R. Soc. Open Sci. 8: 210530*.

Gurevich, Y., Ram, Y. & Hadany, L. 2021. Modeling the evolution of SARS-CoV-2 under non-

pharmaceutical interventions. *medRxiv*.2021.02.20.21252133

Hart, W.S., Miller, E., Andrews, N.J., Waight, P., Maini, P.K., Funk, S., *et al.* 2022. Generation

time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. *Lancet*

Infect. Dis. **3099**: 15–20.

Hartfield, M. & Alizon, S. 2014. Epidemiological Feedbacks Affect Evolutionary Emergence of

Pathogens. *Am. Nat.* **183**: E105-17.

Kucharski, A. & Gog, J.R. 2012. Influenza emergence in the face of evolutionary constraints.

Proc. R. Soc. B Biol. Sci. **279**: 645–652.

Li, Y., Campbell, H., Kulkarni, D., Harpur, A., Nundy, M., Wang, X., *et al.* 2021. The temporal

association of introducing and lifting non-pharmaceutical interventions with the time-

varying reproduction number (R) of SARS-CoV-2: a modelling study across 131

countries. *Lancet Infect. Dis.* **21**: 193-202.

Lipsitch, M. 1997. Vaccination against colonizing bacteria with multiple serotypes. *Proc.*

Natl. Acad. Sci. U. S. A. **94**: 6571–6576.

Liu, Y., Morgenstern, C., Kelly, J., Lowe, R. & Jit, M. 2021. The impact of non-pharmaceutical

interventions on SARS-CoV-2 transmission across 130 countries and territories. *BMC*

Med. **19**: 40.

Lourenço, J. & Recker, M. 2010. Viral and epidemiological determinants of the invasion

dynamics of Novel Dengue Genotypes. *PLoS Negl. Trop. Dis.* **4**: e894.

McClean, A.R. 1995. Vaccination, evolution and changes in the efficacy of vaccines: A

theoretical framework. *Proc. R. Soc. B Biol. Sci.* **261**: 389–393.

Miller, I.F. & Metcalf, C.J. 2019. Vaccine-driven virulence evolution: Consequences of

unbalanced reductions in mortality and transmission and implications for pertussis

vaccines. *J. R. Soc. Interface* **16**: 20190642.

Moore, S., Hill, E.M., Tildesley, M.J., Dyson, L. & Keeling, M.J. 2021. Vaccination and non-

pharmaceutical interventions for COVID-19: a mathematical modelling study. *Lancet*

Infect. Dis. **S1473**-**3099**: 00143–2.

Newbold, S.C., Finnoff, D., Thunström, L., Ashworth, M. & Shogren, J.F. 2020. Effects of

physical distancing to control COVID-19 on public health, the economy, and the

environment. *Environ. Resour. Econ.* **76**: 705–729.

Porco, T.C., Lloyd-Smith, J.O., Gross, K.L. & Galvani, A.P. 2005. The effect of treatment on

pathogen virulence. *J. Theor. Biol.* **233**: 91-102.

Read, A.F., Baigent, S.J., Powers, C., Kgosana, L.B., Blackwell, L., Smith, L.P., *et al.* 2015.

Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens. 1–

18.

Saad-Roy, C.M., Morris, S.E., Metcalf, C.J.E., Mina, M.J., Baker, R.E., Farrar, J., *et al.* 2021.

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing

regimes. *Science.* **372**: 363-370.

Sah, P., Vilches, T.N., Moghadas, S.M., Fitzpatrick, M.C., Singer, B.H., Hotez, P.J., *et al.* 2021.

Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19

variants. *EClinicalMedicine* **35**: 100865.

Sandmann, F.G., Davies, N.G., Vassall, A., Edmunds, W.J., Jit, M. & CMMID COVID-19

working group. 2021. The potential health and economic value of SARS-CoV-2

vaccination alongside physical distancing in the UK: a transmission model-based future

scenario analysis and economic evaluation. *Lancet Infect. Dis.* **S1473**-**3099**: 00079–7.

Smith, C., Yates, C. & Ashby, B. 2022. Critical weaknesses in shielding strategies for COVID-

19. *PLOS Glob. Public Heal. Glob. Public Heal.* in press.

Smith, C.A. & Ashby, B. 2022. Antigenic evolution of SARS-CoV-2 in immunocompromised

hosts. *medRxiv* 2022.01.13.22269154.

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., *et al.*

2021. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**: 438–

443.

Thompson, R.N., Gilligan, C.A. & Cunniffe, N.J. 2018. Control fast or control smart: When

should invading pathogens be controlled? *PLoS Comput. Biol.* **14**: e1006014.

Thompson, R.N., Hill, E.M. & Gog, J.R. 2021. SARS-CoV-2 incidence and vaccine escape.

Lancet Infect. Dis. **S1473**-**3099**: 00202–4.

Thompson, R.N., Hollingsworth, T.D., Isham, V., Arribas-Bel, D., Ashby, B., Britton, T., *et al.*

2020. Key questions for modelling COVID-19 exit strategies. *Proc. R. Soc. B* **287**:

20201405.

Thompson, R.N., Stockwin, J.E., van Gaalen, R.D., Polonsky, J.A., Kamvar, Z.N., Demarsh,

P.A., *et al.* 2019a. Improved inference of time-varying reproduction numbers during

infectious disease outbreaks. *Epidemics* **29**: 100356.

Thompson, R.N., Thompson, C.P., Pelerman, O., Gupta, S. & Obolski, U. 2019b. Increased

frequency of travel in the presence of cross-immunity may act to decrease the chance

of a global pandemic. *Philos. Trans. R. Soc. B* **374**: 20180274.

van Boven, M., Mooi, F.R., Schellekens, J.F.P., De Melker, H.E. & Kretzschmar, M. 2005.

Pathogen adaptation under imperfect vaccination: Implications for pertussis. *Proc. R.*

Soc. B Biol. Sci. **272**: 1617–1624.

Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., *et al.* 2021. Assessing

540   transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* **593**: 266–269.

541   Watkins, E.R., Penman, B.S., Lourenço, J., Buckee, C.O., Martin, C., Maiden, M.C.J., *et al.*

542   2015. Vaccination Drives Changes in Metabolic and Virulence Profiles of Streptococcus

543   pneumoniae. *PLoS Pathog.* **11**: e1005034.

544   Williams, P.D. & Day, T. 2008. Epidemiological and evolutionary consequences of targeted

545   vaccination. *Mol. Ecol.* **17**: 485–499.

546   Wilson, J.N., Nokes, D.J. & Carman, W.F. 1998. Current status of HBV vaccine escape variants

547   - A mathematical model of their epidemiology. *J. Viral Hepat.* **5**: 25–30.

548